Prime Healthcare Achieves National Recognition for Exemplary Social Responsibility by Lown Institute
Recognized for health equity and patient outcomes, 46 Prime hospitals received top 'A' grades on the 2025-26 Lown Index, reflecting the system's commitment to socially responsible care.
Share
Eight Prime hospitals earned top ranks in their states across various domains, including health equity, patient safety and community impact:
Saint Francis Hospital ranked No. 1 in the nation for Pay Equity and #1 in Illinois for Pay Equity
Saint Mary of Nazareth Hospital ranked No. 1 in Illinois for Health Equity
East Liverpool City Hospital ranked No. 1 in Ohio for Social Responsibility and Pay Equity
Garden City Hospital ranked No. 1 in Michigan for Patient Safety
Landmark Medical Center ranked No. 1 in Rhode Island for Health Equity, Inclusivity and Pay Equity
North Vista Hospital ranked No. 1 in Nevada for Social Responsibility, Health Equity, Community Benefit, Inclusivity and Racial Inclusivity
Providence Medical Center ranked No. 1 in Kansas for Social Responsibility
Saint Clare's Denville ranked No. 1 in New Jersey for Avoiding Overuse
The Lown Institute Hospitals Index is an independent national ranking that evaluates hospitals on more than 50 metrics across equity, value and outcomes—factors often overlooked in traditional hospital ratings.
'Hospitals are facing unprecedented political and financial challenges,' said Vikas Saini, MD, president of the Lown Institute. 'In this uncertain environment, it's more important than ever to support the socially responsible hospitals who are delivering high-quality care to all in their community.'
Prime Healthcare continues to strengthen its mission to save and improve hospitals through measurable results. The system's strong showing across the Index reflects focused investments in care quality, physician leadership and a commitment to serving vulnerable and underserved populations.
'Social responsibility and health equity are not just goals—they are a reflection of our purpose as a healthcare organization,' said Sunny Bhatia, MD, President and Corporate Chief Medical Officer of Prime Healthcare. 'It is a profound responsibility and honor to care for our communities, and I commend our caregivers for the compassion, excellence and integrity they bring to every patient encounter.'
Sixteen of the hospitals recognized this year are not-for-profit facilities supported by the Prime Healthcare Foundation, reinforcing the Foundation's mission to expand access and advance health equity in underserved communities.
'We are proud of the extraordinary physicians and staff at our Foundation hospitals who bring our mission to life each day,' said Kavitha Bhatia, MD, President and Chair of the Prime Healthcare Foundation. 'Their unwavering commitment to compassionate, high-quality care ensures that dignity, respect and equity remain central to every patient experience. This recognition is a testament to their leadership and dedication.'
Four Prime Healthcare hospitals earned a spot on the prestigious Lown Institute Honor Roll, receiving straight 'A' grades across all measured categories, including Social Responsibility, Health Equity, Value of Care and Patient Outcomes:
The Lown Hospitals Index for Social Responsibility is the only ranking to combine metrics of health equity and value of care alongside patient outcomes for more than 2,700 acute care and 800 critical access hospitals nationwide, offering a holistic view of hospitals as total community partners. In the sixth annual rankings, the 2025-26 Lown Index evaluates hospitals on over 50 measures including novel metrics such as community benefit, racial inclusivity, and avoidance of overuse. Data sources include Medicare fee-for-service and Medicare Advantage claims, CMS patient safety data and hospital cost reports, and IRS 990 forms, among others. Full methodology can be found on the Lown Index website.
The full list of the 46 Prime Healthcare/Prime Healthcare Foundation 2025-26 Lown Institute Hospitals Index awardees is as follows: Centinela Hospital Medical Center, Inglewood, CA; Chino Valley Medical Center; Chino, CA; Coshocton Regional Medical Center, Coshocton, OH; Dallas Medical Center, Dallas, TX; Dallas Regional Medical Center, Mesquite, TX; Desert Valley Hospital, Victorville, CA; East Liverpool City Hospital, East Liverpool, OH; Encino Hospital Medical Center, Encino, CA; Garden City Hospital, Garden City, MI; Garden Grove Hospital Medical Center, Garden Grove, CA; Harlingen Medical Center, Harlingen, TX; Huntington Beach Hospital, Huntington Beach, CA; Knapp Medical Center, Weslaco, TX; La Palma Intercommunity Hospital, La Palma, CA; Lake Huron Medical Center, Port Huron, MI; Landmark Medical Center, Woonsocket, RI; Lehigh Regional Medical Center, Lehigh Acres, FL; Lower Bucks Hospital, Bristol, PA; Mercy Medical Center, Aurora, IL; Mission Regional Medical Center, Mission, TX; Monroe Hospital, Bloomington, IN; Montclair Hospital Medical Center, Montclair, CA; North Vista Hospital, North Las Vegas, NV; Paradise Valley Hospital, National City, CA; Providence Medical Center, Kansas City, KS; Resurrection Medical Center, Chicago, IL; Riverview Regional Medical Center, Gadsden AL; Roxborough Memorial Hospital, Philadelphia, PA; Saint Clare's Denville, Denville, NJ; Saint Francis Hospital, Evanston, IL; Saint Joseph Hospital, Elgin, IL; Saint Joseph Medical Center, Joliet, IL; Saint Mary of Nazareth Hospital, Chicago, IL; Saint Mary's Regional Medical Center, Reno, NV; Saint Michael's Medical Center, Newark, NJ; San Dimas Community Hospital, San Dimas, CA; Shasta Regional Medical Center, Redding, CA; Sherman Oaks Hospital, Sherman Oaks, CA; Southern Regional Medical Center, Riverdale, GA; St. Francis Medical Center, Lynwood, CA; St. Joseph Medical Center, Kansas City, MO; St. Mary's General Hospital, Passaic, NJ; St. Mary's Hospital, Kankakee, IL; St. Mary's Medical Center, Kansas City, MO; Suburban Community Hospital, Norristown, PA; West Anaheim Medical Center, Anaheim, CA.
About Prime Healthcare and Prime Healthcare Foundation
Prime Healthcare is an award-winning health system operating 51 hospitals and more than 360 outpatient locations in 14 states, providing over 2.5 million patient visits annually. It is one of the nation's leading health systems, with nearly 57,000 employees and physicians. Eighteen of the Prime Healthcare hospitals are members of the Prime Healthcare Foundation, a 501(c)(3) not-for-profit public charity. Based in Ontario, California, Prime Healthcare is nationally recognized for award-winning quality care and has been named a 10 Top and 15 Top Health System by Truven Health Analytics. Its hospitals have been named among the nation's '100 Top Hospitals' 72 times and is one of Healthgrades most awarded health systems in the nation for patient safety. To learn more, please visit primehealthcare.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy.
Business Wire
12 hours ago
- Business Wire
Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company', NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at 'It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,' said Andrew Dudum, co-founder and CEO. 'We believe we're entering an exciting period of growth where we'll enter new, high-impact specialties that bring millions of people in need of care into the market. We expect this broadening offering will transform our platform from a place where customers come to solve a single issue, to one where customers can proactively manage their overall health.' Yemi Okupe, CFO, stated, 'We're seeing consistent growth across our business as we continue to democratize access to precision care. In the second quarter, revenue grew 73% and Adjusted EBITDA more than doubled relative to the prior year; both were driven by robust growth in Subscribers utilizing personalized treatment plans. As we move into the second half of 2025, our focus is on investing in capabilities that will deepen the value customers can access on our platform. This includes plans to strengthen the personalization infrastructure in our pharmacies, to expand lab testing capabilities to further tailor care, and to grow our international presence in key markets.' Second Quarter 2025 Financial Highlights Revenue was $544.8 million for the second quarter of 2025 compared to $315.6 million for the second quarter of 2024, an increase of 73% year-over-year. Gross margin was 76% for the second quarter of 2025 compared to 81% for the second quarter of 2024. Net income was $42.5 million for the second quarter of 2025 compared to $13.3 million for the second quarter of 2024. Adjusted EBITDA was $82.2 million for the second quarter of 2025 compared to $39.3 million for the second quarter of 2024. Net cash used in operating activities was $(19.1) million for the second quarter of 2025 compared to net cash provided by operating activities of $53.6 million for the second quarter of 2024. Free Cash Flow was $(69.4) million for the second quarter of 2025 compared to $47.6 million for the second quarter of 2024. Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income and net cash (used in) provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States ('U.S. GAAP'), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading 'Non-GAAP Financial Measures'. Financial Outlook Hims & Hers is providing the following guidance: For the third quarter 2025, we expect: Revenue of $570 million to $590 million. Adjusted EBITDA of $60 million to $70 million, reflecting an Adjusted EBITDA margin of 11% to 12%. For the full year 2025, we expect: Revenue of $2.3 billion to $2.4 billion. Adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%. The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the 'Cautionary Note Regarding Forward-Looking Statements' safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See 'Non-GAAP Financial Measures' for additional important information regarding Adjusted EBITDA. Conference Call Hims & Hers will host a conference call to review the second quarter 2025 results on August 4, 2025, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results. For more information, please visit Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe,' 'estimate,' 'anticipate,' 'expect,' 'assume,' 'imply,' 'intend,' 'plan,' 'may,' 'will,' 'potential,' 'project,' 'predict,' 'continue,' 'could,' 'confident,' 'confidence,' or 'should,' or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions, the success of our business model, our market opportunity, our ability to scale our business and expand internationally, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the 'Commission'). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the 'Risk Factors' section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods. Key Business Metrics 'Online Revenue' represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. 'Wholesale Revenue' represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms. 'Subscribers' are customers who have one or more 'Subscriptions' pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. 'Monthly Online Revenue per Average Subscriber' is defined as Online Revenue divided by 'Average Subscribers', which amount is then further divided by the number of months in a period. 'Average Subscribers' are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2. December 31, 2024 Assets Current assets: Cash and cash equivalents $ 1,124,582 $ 220,584 Short-term investments 20,033 79,667 Inventory 141,800 64,427 Prepaid expenses and other current assets 69,151 31,153 Total current assets 1,355,566 395,831 Restricted cash 368 856 Goodwill 117,753 112,728 Property, equipment, and software, net 205,480 82,083 Intangible assets, net 40,657 43,410 Operating lease right-of-use assets 71,661 10,881 Deferred tax assets, net 84,229 61,603 Other long-term assets 1,868 147 Total assets $ 1,877,582 $ 707,539 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 105,009 $ 91,180 Accrued liabilities 65,671 53,013 Deferred revenue 98,417 75,285 Operating lease liabilities 3,135 1,889 Total current liabilities 272,232 221,367 Convertible senior notes, net 969,467 — Operating lease liabilities 71,786 9,456 Other long-term liabilities 1,401 — Total liabilities 1,314,886 230,823 Commitments and contingencies Stockholders' equity: Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 217,381,434 and 212,459,586 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2025 and December 31, 2024 23 22 Additional paid-in capital 711,998 719,155 Accumulated other comprehensive income (loss) 822 (324 ) Accumulated deficit (150,147 ) (242,137 ) Total stockholders' equity 562,696 476,716 Total liabilities and stockholders' equity $ 1,877,582 $ 707,539 Expand CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (In Thousands, Except Share and Per Share Data, Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 544,833 $ 315,648 $ 1,130,843 $ 593,819 Cost of revenue 128,637 59,035 283,958 108,111 Gross profit 416,196 256,613 846,885 485,708 Gross margin % 76 % 81 % 75 % 82 % Operating expenses: (1) Marketing 217,862 144,922 449,097 275,475 Operations and support 66,490 41,453 129,523 80,200 Technology and development 37,848 18,654 67,762 33,978 General and administrative 67,273 40,554 115,883 75,122 Total operating expenses 389,473 245,583 762,265 464,775 Income from operations 26,723 11,030 84,620 20,933 Other income and expense, net 6,130 2,394 8,728 4,894 Income before income taxes 32,853 13,424 93,348 25,827 Benefit (provision) for income taxes 9,652 (127 ) (1,358 ) (1,402 ) Net income 42,505 13,297 91,990 24,425 Other comprehensive income (loss) 986 (6 ) 1,146 (44 ) Total comprehensive income $ 43,491 $ 13,291 $ 93,136 $ 24,381 Net income per share attributable to common stockholders: Diluted $ 0.17 $ 0.06 $ 0.37 $ 0.11 Weighted average shares outstanding: Basic 224,373,375 214,618,037 223,187,936 214,035,065 Expand CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands, Unaudited) Six Months Ended June 30, 2025 2024 Operating activities Net income $ 91,990 $ 24,425 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 18,741 6,644 Stock-based compensation 60,584 43,074 Net accretion on securities (1,060 ) (2,281 ) Benefit for deferred taxes (10,346 ) — Impairment of long-lived assets — 114 Amortization of debt discount and issuance costs 1,047 — Non-cash operating lease cost 4,594 1,221 Non-cash acquisition-related costs 2,985 — Non-cash other (1,315 ) 412 Changes in operating assets and liabilities: Inventory (77,373 ) (18,124 ) Prepaid expenses and other current assets (38,081 ) (1,430 ) Other long-term assets (10 ) (47 ) Accounts payable 5,146 16,156 Accrued liabilities 11,737 (24 ) Deferred revenue 23,132 13,257 Operating lease liabilities (1,798 ) (1,140 ) Earn-out payable — (2,825 ) Net cash provided by operating activities 89,973 79,432 Investing activities Purchases of investments — (97,539 ) Maturities of investments 60,569 126,095 Investment in website development and internal-use software (7,961 ) (6,191 ) Purchases of property, equipment, and intangible assets (101,392 ) (13,793 ) Acquisition of business, net of cash acquired (5,100 ) — Net cash (used in) provided by investing activities (53,884 ) 8,572 Financing activities Proceeds from issuance of convertible senior notes, net of debt discount 970,000 — Purchases of capped calls related to convertible senior notes (47,800 ) — Proceeds from exercise of vested stock options 6,497 16,472 Payments for taxes related to net share settlement of equity awards (62,475 ) (22,281 ) Proceeds from employee stock purchase plan 2,970 1,622 Payments for debt issuance costs (3,041 ) — Repurchases of common stock — (47,996 ) Payments for acquisition-related earn-out consideration — (3,190 ) Net cash provided by (used in) financing activities 866,151 (55,373 ) Foreign currency effect on cash and cash equivalents 1,270 1 Increase in cash, cash equivalents, and restricted cash 903,510 32,632 Cash, cash equivalents, and restricted cash at beginning of period 221,440 97,519 Cash, cash equivalents, and restricted cash at end of period $ 1,124,950 $ 130,151 Reconciliation of cash, cash equivalents, and restricted cash Cash and cash equivalents $ 1,124,582 $ 129,295 Restricted cash 368 856 Total cash, cash equivalents, and restricted cash $ 1,124,950 $ 130,151 Supplemental disclosures of cash flow information Cash paid for taxes $ 23,047 $ 3,468 Non-cash investing and financing activities Purchases of property and equipment included in accounts payable and accrued liabilities $ 16,954 $ 1,256 Deferred debt issuance costs included in accounts payable and accrued liabilities 249 — Right-of-use asset obtained in exchange for lease liability 63,434 2,174 Issuance of common stock in connection with asset acquisition 12,760 — Common stock to be issued for asset acquisition indemnification holdback 6,380 — Issuance of common stock for acquisition-related earn-out consideration — 1,396 Expand Non-GAAP Financial Measures In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business. Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. 'Adjusted EBITDA' is defined as net income before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), payroll tax expense related to stock-based compensation, impairment of long-lived assets, interest income and expense, net, and income taxes. 'Adjusted EBITDA margin' is defined as Adjusted EBITDA divided by revenue. In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income and other U.S. GAAP results. Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. 'Free Cash Flow' is defined as net cash (used in) provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities. Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash (used in) provided by operating activities and other U.S. GAAP results.
Business Wire
13 hours ago
- Business Wire
Diversified Healthcare Trust Announces Second Quarter 2025 Results
NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) today announced its financial results for the quarter ended June 30, 2025, which can be found at the Quarterly Reports section of DHC's website at A conference call to discuss DHC's second quarter 2025 financial results will be held on Tuesday, August 5, 2025 at 10:00 a.m. Eastern Time. The conference call may be accessed by dialing (877) 329-4297 or (412) 317-5435 (if calling from outside the United States and Canada); a pass code is not required. A replay will be available for one week by dialing (877) 344-7529; the replay pass code is 1592130. A live audio webcast of the conference call will also be available in a listen-only mode on DHC's website, at The archived webcast will be available for replay on DHC's website after the call. The transcription, recording and retransmission in any way of DHC's second quarter conference call are strictly prohibited without the prior written consent of DHC. About Diversified Healthcare Trust: DHC is a real estate investment trust focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of June 30, 2025, DHC's approximately $6.8 billion portfolio included 341 properties in 34 states and Washington, D.C., with more than 26,000 senior living units, approximately 7.4 million square feet of medical office and life science properties and occupied by approximately 450 tenants. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with approximately $40 billion in assets under management as of June 30, 2025 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA. For more information, visit A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq. No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.
